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ABSTRACT 
 
Background. Gallstones (GS) have historically been thought to be uncommon in 
Sub-Saharan Africa. There are scanty data on the current prevalence of GS in South 
Africa despite a significant change in the GS risk factor prevalence. 
Objectives. To determine the prevalence and risk factors for GS among adult 
patients undergoing abdominal ultrasound scans at a tertiary institution. 
Methods. We conducted a retrospective cross sectional analysis of all adult 
abdominal ultrasound scan reports from the radiology department of the institution in 
the year 2009. Basic demographics, presence, symptoms and complications of 
gallstones were collected.  Logistic regression was used to explore both dependent 
and independent risk factors for developing GS. 
Results. Of the 3 494 reports analysed, 284(8.1%) had GS [95% confidence interval 
7.2 - 9.1], with 70% being female. Gallstone prevalence was 10.2% and 5.5% for 
females and males respectively with a symptomatic to asymptomatic GS ratio of 
1:1.9. Complications were seen in 6.3% of all patients with GS, with cholecystitis 
being the commonest (61%).  The GS prevalence by population group was 
significantly higher in the white population which was an independent risk factor 
[adjusted OR 2.44(1.86-3.20)]. Other independent risk factors for GS were female 
gender [adjusted OR 1.97(1.51-2.56)] and increasing age [adjusted OR 1.03(1.02-
1.04)]. 
Conclusion. In this hospital based study, the prevalence of GS among adult patients 
was slightly higher than in other previous African studies.  Independent risk factors 
for GS were increasing age, white race and female gender. Further community 
based surveys are necessary to determine the true prevalence of GS among adults 
in South Africa. 
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Chapter 1: Introduction 
1.1 Introduction 
The chapter begins with a general overview of gallstones (GS). Details of the 
pathophysiology, risk factors and clinical presentation of GS are subsequently 
explored. The change in the risk factors for GS over time and the possible 
implications thereof on the prevalence of GS in South Africa are discussed. The 
published literature on various aspects of GS is reviewed and the chapter concludes 
with a description of the aims and objectives of the study. 
Bile is an important physiological fluid of the human body that is synthesised by 
hepatocytes in the liver (1). It is stored in the gallbladder, an abdominal organ that 
lies beneath the liver. (See Figure 1.1)  
 
 
Figure 1:1 Anatomy of the liver and gallbladder.(Adapted from Seeds of life)(2) 
Bile predominantly consists of 97% water. The other 3% is made up of bile salts, 
phospholipids, cholesterol and other constituents (1,3). (See Figure 1.2) 
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Figure 1.2: The composition of bile (excluding water) 
Bile has several physiological functions in the body which include: 
 (i) Excretion of potentially harmful lipophilic substances such as exogenous drugs 
and environmental toxins as well as endogenous substances such as bilirubin and 
bile salts (4,5).  
 (ii) Digestion of fat through the emulsification of dietary lipids by bile salts which are 
contained in the bile, thus facilitating intestinal absorption of fat (3,4,6). 
 (iii) Cholesterol excretion. Bile salts are synthesized from cholesterol and bile is the 
major route by which the body excretes cholesterol (4,6). 
(iv) The excretion of immunoglobulin A (IgA) and inflammatory cytokines. These 
once  excreted in bile stimulate the innate immune system in the intestine which 
protects against enteric infections (4). 
 (v) Bile salt reabsorption in the distal small bowel. This is known as the entero-
hepatic circulation and is the main route of absorption of fat dependent dietary 
micronutrients such as Vitamin A, D, E and K (3,4,6). 
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In the gall bladder, the bile salts and phospholipids form micelles around cholesterol 
molecules. This keeps cholesterol in a soluble state and maintains bile in liquid form 
(3). The equilibrium of bile constituents can be altered through various intrinsic and 
environmental factors (7). (See Figure 1.3) Disturbances in this balance results in the 
precipitation of one or more of the bile constituents leading to the formation of 
gallstones (GS) (8). 
 Gallstones have been part of human pathology since ancient times. Archaeological 
data documents GS in mummified bodies of ancient Egyptian and Japanese royalty 
from 1 400 BC (9,10). Today, GS are a common health disorder especially in 
western countries (11,12). They are the leading cause of in-hospital admissions 
amongst all digestive disorders in the United States of America (USA) (11,12). About 
US$6.5 billion is spent annually in the (USA), in direct hospital related costs as well 
as indirect costs such as employee absenteeism and poor quality of life for those 
affected (13). 
Gallstones are classified into cholesterol, pigment and rare stones (3). This 
classification is based on the predominant chemical composition and gross 
appearance of the GS (3). Cholesterol rich stones are the commonest and constitute 
about 75% of all GS. (See Figure 1.4) They are predominantly made up of 
cholesterol crystals, with varying amounts of calcium bilirubinate, calcium carbonate 
and calcium phosphate. Pigment stones are made up of calcium bilirubinate. 
Pigment stones are further sub-classified into black and brown pigment stones. 
Black stones make up approximately 20% of all GS while brown stones account for 
just 4.5%. Rare stones are made up of calcium carbonate stones and fatty acid-
calcium stones (3). 
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Figure 1.3: Pathogenesis of gallstones (Adapted from Premkumar et al) (7) 
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Figure 1.4: Types of gallstones.  
1.2 The pathophysiology of GS 
The pathophysiology of GS differs with each GS subtype. Black pigment stones 
typically form in the gallbladder. They are formed when bile becomes supersaturated 
with bilirubin monoconjugates. The monoconjugates then precipitate with calcium 
ions to form calcium rubinate (14–16).Black pigment GS are commonly associated 
with clinical scenarios in which hyperbilirubinaemia (the availability of large quantities 
bilirubin conjugates from haemolysis) is a predominant feature.  These clinical 
conditions include sickle cell disease and ineffective erythropoiesis among others 
(11). 
Brown pigment stones form in the bile ducts and are more common in Asia where 
they are associated with infection of the biliary system by bacteria or parasites. In the 
west they may occur in the presence of malignant biliary strictures or inflammatory 
strictures as a result of prior biliary system instrumentation e.g. cases of previous 
endoscopic retrograde pancreatography (ERCP) (11,15).  
Cholesterol GS are formed when there is super-saturation of bile with cholesterol. 
This results in the formation of cholesterol micro-crystals in the gallbladder (3,8). 
These micro-crystals deposit around a nidus of bile pigment precipitants or mucus 
proteins forming gallstones that may enlarge over time (3,17).  
75% 
24.5% 
0.5% 
Types of gallstones 
cholesterol stones pigment stones rare stones
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1.3 Risk factors for developing gallstones 
There are multiple established risk factors for developing GS which are shown in 
table 1.1.  
Table 1.1: Risk factors for developing gallstones (Adapted from Stinton et al) (11) 
Non modifiable risk factors Modifiable risk factors 
Family history Metabolic syndrome(Obesity/dyslipidaemia/diabetes) 
Genetic predisposition Sedentary lifestyle 
Female gender Rapid weight loss 
Ethnicity Pregnancy 
Increasing age High fat diet 
 Cirrhosis 
 Crohn’s disease 
 
1.3.1 Non modifiable risk factors  
1.3.1.1 Family history & genetic predisposition  
While no distinct mendelian pattern of GS inheritance has been clearly shown, it is 
apparent that genetic  susceptibility is an important determinant in gallstone disease 
(18).Studies have shown up to five times increased risk of developing GS in relatives 
of GS patients (19,20). A study on 43 141 pairs of twins in Sweden showed 
significantly higher GS in monozygotic versus dizygotic twins (concordance rate 12% 
versus 6%) (20,21).This could have resulted from shared environment being a 
possible mechanism. However this was eliminated by data from studies which 
showed that spouses of affected patients do not have any increased risk of GS (22).  
Mutations in the multidrug resistant protein (MDR3/ABCB4) and cholesterol 7 a 
hydroxilase (CYP7A1) genes are associated with a specific type of cholesterol 
gallstone disease which is characterised by low phospholipid levels (23–26).The low 
phospholipid levels result in precipitation of cholesterol micro-crystals in bile (3). 
However, these genetic mutations are only responsible for a small proportion of 
cholesterol GS (23–26).  
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1.3.1.2 Female gender 
Gallstones tend to be commoner in females than males (11).This has been attributed 
to the female hormones oestrogen and progesterone. Oestrogens stimulate hepatic 
lipoprotein receptors as well as the enzyme 3-hydroxyl-3-methyl-glutaryl co-enzyme 
A (HMG-Co A) reductase (27,28). This is the enzyme that catalyses the rate limiting 
step in cholesterol synthesis. These oestrogen induced changes result in increased 
synthesis of cholesterol by the liver (28). Progesterone causes impaired gallbladder 
emptying leading to stasis which promotes GS formation (3,27,28).  Use of hormonal 
contraception and hormone replacement therapy (HRT) also increase the risk of 
gallstone formation (27).  
1.3.1.3 Ethnicity 
The prevalence of GS varies with ethnicity (11). Table 1.2 shows the difference in 
GS prevalence among various ethnic groups according to community based 
ultrasound studies. More importantly the table also shows the difference in GS 
prevalence among different ethnic groups from the same country i.e. USA. It is 
plausible that the general national GS prevalence of a particular country may not 
necessarily be an accurate reflection of GS prevalence among specific ethnic groups 
(population/racial groups) in that same country. There is a possibility that ethnicity 
may confer a yet unknown genetic risk. 
Table 1.2: Gallstone prevalence according to ethnicity (Adapted from Shaffer E) 
(12) 
Ethnic group Female  prevalence Male  prevalence 
 American Indians 64.1% 29.5% 
White Americans 
(non Hispanic) 
16.6% 8.6% 
Black Americans 13.9% 5.3% 
Mexican American 26.7% 8.9% 
Hispanic American 19.1% 5.4% 
   
Mapuche Indians(Chile) 49.4% 12.6% 
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1.3.1.4 Age 
The risk of GS increases with increasing age becoming 4-10 times more likely in 
individuals over the age of 40 years (11). This could possibly be as a result of other 
GS risk factors that also increase with age such as the metabolic syndrome. Older 
age also means longer exposure to other risk factors e.g. sedentary life style. 
Gallstones being a chronic disorder are also likely to increase with older age (29–
32). Symptoms and complications of GS also increase with age leading to more 
cholecystectomies (32). 
1.3.2 Modifiable risk factors 
1.3.2.1The Metabolic Syndrome 
The metabolic syndrome is associated with increased risk of developing GS as well 
as that of developing GS complications (11,33). Some researchers have advocated 
that GS should be considered a part of the metabolic syndrome due to the very 
strong association (34,35).The metabolic syndrome consists of a constellation of 
clinical features. According to the International Diabetes Federation (IDF) definition, 
for a person to be defined as having the metabolic syndrome they must have: 
 Central obesity defined by ethnic appropriate values for waist circumference* 
plus any two of the following four factors: 
Raised 
triglycerides 
≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid 
abnormality 
Reduced HDL 
cholesterol 
< 40 mg/dL (1.03 mmol/L) in males 
 < 50 mg/dL (1.29 mmol/L) in females  
or specific treatment for this lipid abnormality 
Raised blood 
pressure 
systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 
previously diagnosed hypertension 
Raised fasting 
plasma glucose 
(FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 
2 diabetes If above 5.6 mmol/L or 100 mg/dL, OGTT is strongly 
recommended but is not necessary to define presence of the 
syndrome. 
*If BMI is >30kg/m², central obesity can be assumed and waist circumference does not need to be measured. FPG: fasting 
plasma glucose BP: blood pressure HDL: high density lipoprotein BMI body mass index   OGTT: oral glucose tolerance test  
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Table 1.3: The IDF definition of the metabolic syndrome.  (Adapted from the  
International Diabetes Federation)  (36) 
 
1.3.2.1.1 Obesity  
Gallstones are common in morbidly obese individuals with at least a quarter of them 
harbouring GS (37). The greatest risk of GS in obese individuals has been noted in 
the late teenage years and lean body mass has been shown to protect against GS 
(38,39). There is also some evidence that BMI correlates with GS more in females 
than it does in males (40,41). Adult females with high BMI have a greater risk of 
developing GS compared to males of equal BMI (42).Researchers have proposed 
that this could result from males having a leaner body mass than would females for 
the same BMI (43–45). 
 Individuals with obesity have increased gallbladder volumes as well as increased 
HMG-Co A reductase activity.This results in increased liver synthesis of cholesterol 
and its subsequent secretion into bile thus encouraging GS formation (40,41,46–48). 
1.3.2.1.2 Dyslipidemia 
 Low High Density Lipoprotein (HDL) cholesterol and elevated triglycerides are 
associated with increased risk of developing GS (44,49,50). However there is no 
definite association between hypercholesterolemia and GS (38,51). There is some 
evidence that the use of statins for treating dyslipidaemia reduces the  risk of 
developing GS, though more work is needed to confirm this finding (52). 
1.3.2.1.3 Diabetes 
 In insulin resistance as well as overt diabetes there are changes to gallbladder and 
bile physiology which increase the likelihood of developing GS. These include: 
 easy cholesterol super-saturation of bile secondary to impaired bile salt 
synthesis 
 enhanced cholesterol secretion 
  reduced ejection fraction of the gallbladder secondary to gallbladder 
hypomotility  
  Increased volume of the gallbladder in fasting phase (53–58). 
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1.3.2.1.4 Hypertension 
There is evidence that hypertension is associated with GS (59,60). A study in China 
which consisted of 918 patients with GS and 6652 healthy controls showed that 
systolic blood pressure and diastolic blood pressure were significantly higher in 
patients with GS compared to the controls (61).The exact mechanism by which 
hypertension increases GS risk remains unclear (61). 
1.3.2.2 Sedentary Lifestyle 
 A sedentary life style increases the risk of gallstone disease whereas increased 
physical activity decreases this risk (11). This effect is independent of the role of 
physical activity in weight loss (62,63). In a study of  25 639 volunteers aged 40-74  
from England, increasing endurance exercise to 30 minutes, 5 times weekly was 
associated with a 70% decreased risk of symptomatic gallstones(64). The exercise 
induced reduction in symptomatic GS has been linked to lower rates of 
cholecystectomy amongst asymptomatic GS careers (62,65). 
1.3.2.3 Rapid Weight Loss 
Between 30% and 71% of individuals who undergo rapid weight loss due to calorie 
restriction or bariatric surgery develop GS(66–72).Rapid weight loss, especially that 
exceeding 1.5kg/week increases risk of GS through increasing cholesterol secretion 
by the liver, increasing mucin production by the gallbladder as well as reducing 
gallbladder motility (3,8). 
1.3.2.4 Pregnancy and Parity 
 High oestrogen levels in pregnancy lead to increased cholesterol secretion and 
formation of supersaturated bile. Increased progesterone levels decrease gallbladder 
motility which results in increased gallbladder volume and bile stasis (28). All these 
changes promote GS formation. Increased parity probably increases risk of GS by 
repeatedly exposing a woman to the above mentioned changes (3,27,73).  
1.3.2.5 Diet 
Gallstone prevalence is higher is communities that have calorie dense diets that are 
rich in cholesterol and saturated fatty acids (3). The shift towards a more 
westernized diet among the Japanese was associated with a shift in the prevalent 
gallstones from pigment to cholesterol type (74).This phenomenon was also noted 
after World War II in Europe(38,75,76).Not all individuals develop cholesterol GS as 
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a result of these dietary changes and genetic variations in cholesterol metabolism 
may account for this(77,78). 
1.3.2.6 Total Parenteral Nutrition (TPN) 
Gallbladder emptying is stimulated by the presence of food in the duodenum(3). 
Parenteral nutrition involves the infusion of nutrients directly into the blood stream. 
This bypasses the intestines thereby removing enteric stimulation of the gallbladder. 
This ultimately results in gallbladder stasis and formation of GS (79).  
1.3.2.7 Underlying Chronic Disease 
1.3.2.7.1 Cirrhosis 
Gallstones are about 25% more common in cirrhotic patients when compared to the 
normal population (80).In liver cirrhosis there is altered hepatic bilirubin secretion 
and reduced gallbladder motility which makes cirrhotic patients prone to GS. 
Pigment stones are the commonest type of GS that cirrhotic patients develop (3,80). 
1.3.2.7.2 Chron’s disease 
Chron’s disease is an idiopathic inflammatory bowel disorder. When it involves the 
terminal ileum, it causes a reduction in bile acid re-absorption. This results in 
reduced enterohepatic circulation of bile acids. There is an increased ratio of 
cholesterol to bile acid secretion by the liver resulting in cholesterol super-saturation 
of bile and the consequent formation of GS (8,81). 
1.3.2.7.3 Other diseases  
In cystic fibrosis, bile acid binds to undigested nutrients in the bowel. This reduces 
the enterohepatic circulation of bile acids and increases the risk of GS by 10%-30% 
in a mechanism akin to that observed in Crohn’s disease (82). Chronic haemolysis 
such as that observed in sickle cell disease, leads to excessive bilirubin excretion 
with the formation of black pigment stones (11). The risk of developing GS in 
individuals with spinal cord injury is threefold that of the general population (83–85). 
This probably arises from gallbladder stasis and reduced bowel motilility which alters 
bile acid metabolism (11). 
1.3.2.8. Drugs 
 Somatostatin analogues such as octreotite inhibit cholecystokinin release which 
causes gallbladder hypomotility and stasis of bile (86). Half of patients receiving 
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octreotide develop GS (87,88). Thiazide diuretics cause biliary cholesterol saturation 
thus increasing the risk of GS formation (89). 
 
1.4 The Natural History of Gallstones 
More than 80% of individuals with GS remain asymptomatic throughout their lifetime 
(90). A small percentage of up to 4% develop symptoms annually and up to 10% 
become symptomatic after 5 years of follow up (90–92). Major gallstone 
complications develop in only 1-2% per year (3,74,93).The longer the individual 
harbours GS the less likely they are to develop symptoms. However symptomatic 
GS in older individuals are more likely to complicate when compared to younger 
individuals (32,90). 
1.4.1 Clinical Presentation of Gallstones 
Gallstones can cause clinical symptoms through a myriad of ways. (See Figure1.5)  
Intermittent obstruction of the cystic duct may cause biliary pain which is the 
commonest manifesting symptom of GS (3). It typically is epigastric or right upper 
quadrant pain that may be associated with nausea or vomiting. This pain can last for 
a few hours but may persist for up to 24 hours (3,8). 
Inflammation of the gallbladder as a result of infection arising from an obstructed 
cystic duct is known as acute cholecystitis. In these cases patients may have fever in 
addition to biliary pain (8). Cholecystitis is often preceded by one or more prior 
episodes of biliary pain which may be confirmed on history taking (3). Recurrence is 
common if cholecystitis resolves without surgical intervention (3,94). 
Sometimes a stone impacts in the gallbladder neck or cystic duct and obstructs the 
common bile duct. This is termed the Mirizzi syndrome (8). Choledocholithiais and 
cholangitis are as a result of a stone in the bile duct causing bile stasis and bacterial 
super-infection (3). 
 A gallstone impacting at the level of the ampulla can cause backpressure on the 
pancreas. This then leads to the premature release of pancreatic enzymes resulting 
in pancreatitis (3). 
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Figure 1.5: Clinical syndromes arising from gallstones (Adapted from Wang et 
al) (3) 
 
Longstanding GS may result in gallbladder cancer in less than 0.3% of patients with 
GS 
 Other less common complications of GS include:  
•Gallbladder mucocoele 
•Gallbladder empyema  
•Gangrenous gallbladder 
•Biliary peritonitis 
•Porcelain gallbladder 
•Gallstone ileus (3,8,95) 
1.4.2 Diagnosis of Gallstones 
The principal diagnostic modality for diagnosing GS is abdominal ultrasound scan 
(USS). It is relatively cheap, easy to perform, accurate, readily available and does 
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not expose patients to radiation (3,96). It has a sensitivity of more than 95% for 
stones larger than 2mm and a specificity of more than 95% when stones produce 
acoustic shadows (97). Liver function tests (LFTs) together with  abdominal USS are 
important initial tests and should be offered whenever there is clinical suspicion of 
GS disease e.g. where a patient presents with abdominal pain, jaundice or fever (98) 
However, LFTs are not reliable and may be normal in the presence of symptomatic 
disease (99). 
Abdominal X-ray is of limited use in the diagnosis of GS. Only 50% of pigment 
stones and 20% of cholesterol stones are radio-opaque (3). With cholesterol stones 
being the commonest GS, use of X-ray in diagnosing GS would miss most of them 
(3). Computed Tomography (CT) scanning is suitable for investigating GS 
complications such as abscess, perforation or pancreatitis. It is less suitable for 
uncomplicated GS as it is  expensive and exposes patients to radiation without 
adding more value than would be obtained though ultrasound imaging (3,8). 
Magnetic Resonance Cholangio-pancreatography (MCRP) is rapid and non invasive 
and shows immense biliary tract anatomical detail (3).  It is therefore useful where 
choledocholithiasis is suspected. It is also recommended where ultrasound is 
suboptimum as a result of overlying bowel gas, large body habitus or other 
operational technical challenges (3,8,100).  
 
Endoscopic retrograde cholangio-pancreatography (ERCP) involves instrumentation 
of the biliary tract system. It is used more for treating confirmed choledocholithiasis 
than for initial GS investigation (98). Its major drawback is the development of 
complications such as pancreatitits which can be fatal (3). Prudent selection of 
patients for ERCP is therefore vital. 
 
Endoscopic ultrasound (EUS) is a non-invasive test that is highly accurate in 
detecting bile duct stones (3). It has limited availability in most non referral centres 
as its  high sensitivity for detecting gallstones  depends on highly experienced 
operators who may not be readily available (3,8). 
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1.4.3 Management of Gallstones 
 Asymptomatic GS do not need any intervention except in some unique patient 
groups at risk of complications or malignancy such as those with porcelain 
gallbladder, immunosupressed patients (e.g. after transplantation) and elderly 
diabetics (101). 
The definitive management for symptomatic GS is a laparascopic cholecystectomy 
(3). It can be performed either at the time of presentation or after the acute 
presenting clinical episode has resolved (3,8). Where patients are unfit for surgery or 
are unwilling to undergo surgery, medical therapy such as extracorporeal shock 
wave lithotripsy (ESWL) or bile acid dissolution therapy with ursodeoxycholic acid 
(UCDA) may be used. Ursodeoxycholic acid reduces biliary cholesterol secretion, 
increases biliary bile acid concentrations, and consequently reduces the cholesterol 
saturation index. It also inhibits biliary secretion of cholesterol, reduces intestinal 
absorption of cholesterol, increases hepatic bile secretion, and improves gallbladder 
emptying(15).  
Extracorporeal shock wave lithotripsy utilises high energy shock waves generated by 
an electrical discharge to fragment GS (102). Both UDCA and ESWL are however 
less successful when compared to cholecystectomy. Therapy with UDCA and ESWL 
is only successful in 27% and 50% of patients respectively (15). Approximately 40% 
of patients will have recurrence of GS when treated with these non surgical 
interventions (103,104). Where patients present with choledocholithiasis, ERCP prior 
to cholecystectomy is recommended to clear the bile duct of stones (8). 
Although sustained weight loss and increased physical activity can help in preventing 
the development of gallstones they are of little benefit in those with symptomatic GS 
(62).  
1.5 South African Background 
South Africa has a population of 51.8 million people. Females make up just over half 
of this population at 51.3% and males constitute the remaining 48.7%. The 
population is generally young with a median age of 25 years. The racial distribution 
amongst the general population of South Africa is Blacks 79.2%, Whites 8.9%, 
Coloureds 8.9% and Indian/Asian 2.5% (105). Urbanisation in South Africa has 
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increased. This is evidenced by an increase in the proportion South Africans living in 
urban areas from 56.3% in 2001 to 64% in 2014 (106,107). 
Obesity is highly prevalent in South Africa. About 70% of South African women 
above the age of 37 years are overweight or obese (108). A Lancet survey published 
in 2013 also showed that 69.3% of South African women above the age of 20 years 
are either overweight or obese and 42% of them are obese (109). Diabetes and 
dyslipidaemia have also been increasing among studied urban South African 
populations (110–112). In a study by Levitt et al the proportion of life spent in an 
urban area was an independent risk factor for developing diabetes among South 
Africans living in urban areas. (110)  
 
South Africa also has one of the highest HIV/AIDS burdens in the world. There are 
about 7 million South Africans living with HIV/AIDS (113). About one fifth of South 
African women in their reproductive age are HIV positive (114). The use  of highly 
active antiretroviral treatment (HAART) especially the protease inhibitors is 
associated with the development of lipodystrophy, dyslipidaemia and truncal obesity 
with insulin resistance which may progress to overt diabetes (111,115). 
Dyslipidaemia, obesity and the metabolic syndrome will likely increase over time as 
more South Africans access HAART. 
Physical inactivity is common among South African adults, with 48% of men and 
63% of women being classified as inactive in a Department of Health survey (116). 
Over time the South African diet has changed towards a more westernized calorie 
dense diet with a high fat content (116,117).  All these factors interplay in increasing 
the risk of developing GS in the South African population. 
 
1.6 Literature Review 
1.6.1 Prevalence of Gallstones 
Ultrasound based surveys have shown varying gallstone prevalence across the 
world .Gallstones tend to be commoner in the western world and less common in 
Asian and African countries. (See Fig 1.6)  
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Figure 1.6: Female worldwide gallstone prevalence based on  ultrasound 
surveys (Adapted from Stinton L) (11) 
A population based ultrasound survey of gallstones was carried out in the USA as 
part of the third National Health and Nutrition Examination Survey (NHANES III). 
Over 14 000 participants made up the representative sample that was examined. 
The overall GS prevalence was 7.9% for men and 16.6% among women. The study 
sample was diverse and is one of the few studies that explore GS prevalence among 
different ethnic groups in the world. The highest GS prevalence of 26.7% was seen 
among Mexican American women and the lowest of 5.3% was noted among Black 
American males. Prevalence was as high as 76.1% in American Indian women over 
the age of 65 from Arizona. In this study GS prevalence was higher with full- Indian 
heritage than in those with mixed heritage (118). 
Gallstone prevalence in Europe is comparable to that in the USA with the mean 
European prevalence at 18.5% (99). The lowest prevalence of 5.9% was reported in 
Italy while the highest of 21.9% was recorded in a Norwegian study that looked at 
2 464 individuals between the ages of 20 and 70 years (119,120).  
 18  
 
In South America a study in Peru showed an overall prevalence of 14.3% while two 
Argentine studies found prevalence of 20.5% and 21.9%. Amerindian genetic 
admixture may be responsible for this high GS prevalence. Data from Chile 
documents GS prevalence of 67% and 45% among Mapuche Indian females and 
males respectively (121–124). 
Data from Asian studies conducted in Japan, Taiwan, China, Bangladesh and India 
showed GS prevalence ranging from 3.2% to 22.87% (42,125–131). Prevalence was 
generally low in these studies with the highest prevalence of 22.87% being observed 
in a selected sub-population that had multiple modifiable risk factors for GS (127). In 
the Middle East, data from two Iranian studies showed prevalence of 0.8% and 4.7% 
(132,133).  
Earlier post mortem based studies in Africa failed to show any GS (134). This 
literature was based on the Masaai tribe of northern Kenya and southern Tanzania. 
The Masaai are a unique group of people who are nomads and are not exposed to  
most GS risk factors (11). Therefore this study result cannot be generalised to all 
African populations. Since the study was post-mortem based, GS prevalence among 
the living was not explored. 
There are few community based ultrasound surveys in Africa probably as a result of 
the lack of funding and unavailability of multidisciplinary personnel required to 
conduct such studies. One such study conducted in Sudan showed a GS prevalence 
of 5.2% (135).The study however had a small sample size of 242. In Tunisia, a study 
of 1 123 adults from a small town in central Tunisia showed GS prevalence of 4% 
which is lower than western based studies (11,136). Data from hospital based 
ultrasound studies in Africa shows prevalence of 2.9%, 5.9% and 5.2% for Nigeria, 
Ghana and Ethiopia respectively (137–139). In South Africa a survey of 100 black 
elderly women from Soweto showed a GS prevalence of 10% (140). 
1.6.2 Risk Factors for Gallstones 
1.6.2.1 Gender 
Data from multiple studies shows that GS are more common in females than they 
are in males (118,122–124,131). However two studies from Taiwan showed a 
different result with no significant difference in GS prevalence between males and 
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females (42,126). A large study in China of over a million adults who were mostly 
urban government and local company employees, showed an overall GS prevalence 
of 4.6%, with males having a statistically significant higher prevalence than females. 
(141). Males also had more GS than females in a study by Nomura et al in Japan 
(125).These findings are different from western studies where the predominant type 
of GS are cholesterol stones(3). Asian studies have shown that pigment stones are 
commoner than cholesterol stones in this part of the world (11,127).Since pigment 
stones are associated with biliary tract bacterial and parasitic infections there is 
unlikely to be a gender difference in the prevalence. 
1.6.2.2. Family History 
An Italian study found a significantly higher prevalence of GS in 202 first degree 
relatives of GS patients compared to controls (19). This is in keeping with other 
studies done in Argentina, India and Taiwan (42,123,130). The study in Peru found 
that there was a higher likelihood of GS if there was another person from the same 
household who also had GS (122). This could have resulted from possible genetic 
risk or shared environmental risk factors. A French study of 1 322 subjects did not 
find an association between family history and GS (142). This suggests that there 
are more complex factors involved in gallstone formation other than a positive family 
history alone. 
1.6.2.3 Pregnancy and parity 
Data from western countries shows that 12% of pregnant women develop GS and 1-
3% of these women develop complications that require surgery (28). A study 
conducted in Nigeria showed different results with only 2.9% of women attending an 
antenatal clinic having GS on ultrasound and just 0.2% of them developing 
complications (137). This low prevalence could have resulted from the study being 
carried out in a setting of a low general GS prevalence compared with western 
based studies (11,12).  
 Walker et al described a higher prevalence among Sowetan women compared to 
that described for Nigerian women by Ibitoye et al. (137,140). This difference may be 
explained by the fact that women attending the antenatal clinic were younger, 
premenopausal women (age range 14 - 43 years) and may have had lower parity 
unlike the population studied in Soweto who were older (age range 55 - 85 years) 
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and possibly had higher parity. Increasing age and parity are risk factors for 
developing GS (11). Parity was shown to be a risk factor for GS in studies conducted 
in Peru, North India and Sweden (122,130,143). However a French study showed 
that parity was not a risk factor for GS (142). The definition of parity used in the 
French study was ‘one or more pregnancies’ as opposed to other studies that 
differentiated degree of parity such as the Peruvian study which showed that parity 
of greater than 4 significantly increased GS risk (122). A higher parity probably 
increases a woman’s duration of exposure to the lithogenic hormonal changes 
associated pregnancy. 
1.6.2.4 Oral Contraceptive Pill (OCP) 
Use of the OCP was reported as a risk factor for GS in studies conducted in 
Sweden, Peru and Taiwan however literature from France does not support this 
finding (42,122,142,143). The French study excluded women who were under 30 
years old and as such excluded a significant proportion of women using OCP and 
this may have impacted their results (142). 
1.6.2.5 Diabetes 
A number of studies have shown an association between diabetes and GS 
(42,130,133). A study of 889 diabetic patients in Italy showed an overall GS 
prevalence of 30.4% (15.5% for males and 38.6% for females) (144). This as 
expected was much higher than that of the general Italian population shown in the 
Multicentrica Italiana COLelitiasi (MICOL) study which showed a prevalence of 6.5% 
males and 10.5% for females respectively. Agunloye et al found a GS prevalence of 
17.5% among Nigerian diabetic patients (145). This is much lower than that seen in 
the Italian diabetic patients perhaps because the background GS prevalence of 
African countries is generally lower than that of western countries (11,12). 
 There are some studies that have shown no association between diabetes and GS. 
These include a study of 1 322 individuals from Southeast France and another one 
of 1 721 vegetarian volunteers of the Buddhist Tzu Chi Foundation in Taiwan 
(126,142). 
1.6.2.6 Obesity 
The study in Tunisia concluded that there was no association between BMI and GS 
(136). This is unlike the conclusions drawn from multiple studies from the UK, 
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France, Argentina and Nigeria (64,124,136,142,145).The definition of obesity used in 
the Tunisian study was: BMI > 27kg/m2 in males and BMI > 25kg/m2 in females 
(136). However, obesity is defined by the World Health Organisation (W.H.O.) as a 
BMI > 30kg/m2 (146). There were very few participants in the study who met this 
widely accepted definition of obesity. This could explain the different findings in this 
study regarding the relationship between BMI and GS when comparing with other 
studies. The French study also did not find an association between obesity and GS 
which again contradicts most literature (142). 
1.6.2.7 Dyslipidaemia 
Studies show conflicting data on the relationship between dyslipidaemia and GS. A 
Swedish study by Halldestam et al and a Chinese survey of the Uinghur ethnic group 
showed a strong relationship between hypercholestrolaemia and GS(127,147). This 
finding is opposed to data from a Swedish study by Borch et al as well as data from 
Argentina (124,143). In their study from Norfolk, Banim et al described high HDL 
cholesterol levels as protective against GS and that hypertriglyceridaemia was 
associated with GS, a finding that was also documented by Alfredo (64,124).The use 
of lipid lowering statins to treat dyslipidaemia have been associated with a reduced 
risk of developing GS (52). 
1.6.2.8 Diet 
A  Chinese study compared GS prevalence between two ethnic groups. Their results 
showed that the Uinghur Chinese had a GS prevalence of 22.87% while that of the 
Han Chinese was 11.64%(127).The differences between the two ethnic groups were 
probably due to environmental factors such as diet. The Uighur Chinese diet is more 
westernized with a higher fat and low fibre content which is known to promote GS 
formation (11). This was further supported by the finding that the Uighur Chinese 
developed more of cholesterol stones which were more frequently located in the GB. 
While the Han group mostly developed pigment stones in the intrahepatic ducts 
(127). Cholesterol GS have been linked to westernised diets (38,75,76). 
In a study among urban based Taiwanese vegetarians, the GS prevalence was 8.2% 
which was higher than that of 5.0% found in a study that included non vegetarians 
from a Taiwanese village (42,126). The Taiwanese studies do not agree with 
literature that suggests that the high fibre content in vegetarian diets may protect 
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against GS formation (11,131).The increase in fried foods among urbanised 
Taiwanese vegetarians could account for the higher than expected GS prevalence 
among urban dwelling vegetarians (126). 
1.6.2.9 Socioeconomic Classification (SEC) 
There is conflicting data in literature regarding the relationship between SEC and 
GS. This likely stems from a lack of uniformity in the SEC determination methods 
used in the various studies. A study conducted in the USA among populations of 
differing SEC found an inverse relationship between GS and SEC (148). In a 
Bangladeshi study of 1 019 adults, GS were more common among those of middle 
to low SEC (128). This observation was also noticed in a British study by Murray et 
al (149).  
 The Chinese study carried out in Xinjiang, a predominantly low SEC region, yielded 
a higher GS prevalence compared to studies carried out in more affluent areas of 
China (127). Pigment stones which are more common in Asian countries are 
associated with biliary parasitic infections and are therefore likely to be more 
common in lower SEC regions where sanitation is likely to be poorer than in affluent 
regions. 
 However a study in the rural Gangetic basin of northern India showed that higher 
SEC was a risk factor for GS (130).A study conducted in rural Bangladeshi by Dhar 
et al also showed a similar result (129).It is possible that in these two studies a 
higher SEC may have been an indirect marker of a westernised lifestyle in a rural 
setting, which is associated with an increased the risk of developing cholesterol GS. 
Gallstone sub-typing was however not explored in these studies. 
1.6.2.10 Drugs 
There is some evidence that suggests that use of thiazide diuretics modestly 
increases the risk of GS formation. Leitzmann et al conducted a prospective study of 
81 351 US women aged between 30 and 55 years who were using thiazide diuretics. 
Their results showed that the relative risk of cholecystectomy rose 36% and 57% for 
past and current thiazides users respectively (150).  
1.6.3 Symptoms of Gallstones 
The prevalence of symptomatic GS in population based studies was 6.3% and 
9.21% in Britain and France respectively (142,151). In rural Bangladesh, 71.9% of 
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the study subjects were asymptomatic (129). These studies are in keeping with the 
natural history of GS (11). In hospital based studies such as Ethiopia the ratio of 
symptomatic to asymptomatic GS was 1:1(139).The high proportion of symptomatic 
GS in this study is probably as a result of a hospital based study having a higher 
likelihood of including more symptomatic patients than would a community based 
study. 
In Chandigarh, India 64.9% of individuals with clinical symptoms suggestive of GS 
had GS confirmed on USS while in northern India only 7,12% of symptomatic 
individuals had confirmed GS (130,131). The difference in prevalence among 
symptomatic patients in these studies may arise from the different subjective terms 
used to describe symptoms in the studies. 
In the Peruvian study abdominal pain, was an unreliable indicator of symptomatic 
gallstones.  Symptoms were almost equally prevalent in subjects with GS and those 
without GS at 13.2% and 15.4% respectively (122). Symptoms ascribed to GS such 
as right upper quadrant pain are not unique to GS alone and may arise from 
pathology in other abdominal organs such as the liver. 
There is a gap in knowledge regarding GS prevalence in Africa and more so in South 
Africa. The increase in GS risk factors such as obesity, sedentary lifestyle and 
dietary westernization among South Africans raises concern as to whether the 
traditional view of GS being rare among Africans is still accurate (11).  
1.7 Study Objectives 
1.7.1 Aim of Study 
The aim of this study is to describe the demographic, clinical and sonographic 
features of GS occurring in adult patients undergoing abdominal ultrasonography in 
the radiology department at Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH).  
1.7.2 Specific Objectives 
The specific objectives of the study are: 
i. To describe the patient characteristics of adults undergoing abdominal USS at 
CMJAH 
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ii. To determine the prevalence of GS in adult patients undergoing abdominal 
ultrasonography at CMJAH.  
iii. To compare  the characteristics of patients who have GS with those without GS 
on abdominal USS 
iv. To investigate risk factors associated with GS 
v. To calculate the ratio of symptomatic GS to asymptomatic GS among those 
diagnosed with GS. 
vi. To explore the reliability of clinical symptoms in correctly identifying patients with 
symptomatic gallstones 
vii. To determine the prevalence of complications among those with GS. 
1.8 Hypotheses 
i. The prevalence of GS in South Africa is higher than previously reported. 
ii. Given that GS prevalence was lowest among Black Americans we expect a 
low GS prevalence amongst Black South Africans compared to other 
population groups in South Africa (12). 
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Chapter 2: Materials and Methods 
 
Introduction 
The study design, site, population and methodology are described in this chapter. 
The methods used for the selection of study participants are explained. The 
definitions of study variables are given. The measures taken to ensure quality data 
are also described. The chapter ends with a review of the data processing methods 
and ethical considerations. 
2.1 Study Design 
This study was a retrospective cross sectional analysis of the USS reports of all 
patients who underwent abdominal USS between January 1st 2009 and December 
31st 2009.  
2.2 Study Site 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) is a quaternary 
academic institution for the University of the Witwatersrand Faculty of Health 
Sciences located in central Johannesburg. The institution has 1088 beds and serves 
as a referral centre for patients across the province of Gauteng as well as other 
neighbouring provinces of South Africa. It is estimated to have 4 000 professional 
and supporting staff offering a wide range of specialized services to inpatients and 
out patients (152). 
2.3 Study Population 
The radiology department at CMJAH performs an excess of 10 000 various 
ultrasound studies each year, a significant proportion of these being abdominal USS. 
This provided a large sample size which increased the power of our study. This 
study was the first hospital based study designed to investigate the prevalence of GS 
among patients presenting for abdominal USS at a quaternary health care institution 
in South Africa. 
2.4 Study Sample 
2.4.1 Sample Size Calculation 
The sample size was calculated using the sampsi command in the STATA version 
13 (STATA Corporation, College Station, TX) software package. A minimum sample 
size of 292 reviewed ultrasound reports was estimated to have 90% power to detect 
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a difference in prevalence of at least 5% using a one-sample comparison to a 
hypothesized value (p=0.052), with a 0.05 two-sided significance level (See 
appendix 1). The Ethiopian study with a prevalence of 5.2% was used in calculating 
the sample size as it is similar to the intended study (139). We however reviewed all 
abdominal USS reports done in the study period to allow for more precise estimates. 
2.4.2 Inclusion Criteria  
All adult patients (≥ 18 years at time of imaging) undergoing an abdominal USS at 
CMJAH department of radiology between January 1st 2009 and December 31st 2009 
were included in the study. 
2.4.3 Exclusion Criteria 
i. Subsequent USS reports in a patient who had had more than one 
investigation were excluded. 
2.5 Data Management  
2.5.1 Data sources 
To get an USS at CMJAH, the requesting physician manually completes an USS 
request form. (See Appendix 2) On this form the requesting physician documents the 
patient demographic details and the radiological investigation being requested. The 
completed form is then submitted to the radiology department where the patient’s 
details are electronically captured into the medicom system to generate a unique X-
ray number that is used to systematically file patient duplicate USS reports in the 
radiology department.  
Medicom is an electronic record keeping system used by the Gauteng department of 
health at CMJAH. Demographic data including self reported race and SEC are 
captured when a patient is first seen at the hospital. This system generates unique 
hospital and X-ray numbers for each patient. The patient information can be 
retrieved from medicom by searching with the patients name and surname, hospital 
number or the X-ray number. 
Once the USS is conducted the sonographer manually writes down the sonographic 
findings onto the USS request form. The original copy of this form is sent with the 
patient back to the requesting doctor and a hard copy of the same form is stored in 
the radiology department archives filing room. These archived reports were 
accessed and patient demographic details, the indication for the USS (based on the 
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patient clinical details supplied by the USS requesting physician) as well as the 
sonographic findings were extracted. The USS reports in most instances did not 
document the patient race, SEC and in some cases patient age. In these instances 
the patient name, hospital number or X-ray number was used to access the 
medicom electronic database to complete the missing information. 
The medicom system uses the CMJAH classification and tariffs categories of 2006 
for SEC stratification of patients which are based on personal or family income and 
assets. These categories classify patients into H0 (formally unemployed pensioners 
who do not pay any hospital fee), H1 (low SEC - annual income of less than 
R36 000), H2 (middle SEC -annual income of R36 000-R72 000), H3 (high SEC - 
annual income of R72 000 or more), emergency patients (life threatening emergency 
medical conditions and do not pay any hospital fees), medical aid patients and 
private ward patient (See Appendix 3).  
2.5.2 Study Variables 
Data was collected using a structured data collection sheet which is attached. (See 
Appendix 4) The following variables were collected and coded: 
 Age was defined as the age in years of the patient at the time of 
undergoing USS. This was calculated from the date of birth and date of 
USS. In the absence of data that recommended categorisation of age, 
this variable was not stratified but rather collected as a continuous 
variable.  
 Sex was defined as sex of the patient which was either male or female. 
 Race was defined as the self identified race which the patient identified 
themselves as when demographic data was captured on the medicom 
system on the patient’s initial visit to the hospital. Race in the medicom 
system is categorised as either White, Black, Asian or Coloured 
 Ward was classified as either inpatients for patients being imaged from 
the hospital wards or casualty and outpatients for patients being 
imaged from the out patients department or other referring health care 
centres. 
 Socio-economic class (SEC) was defined as per the CMJAH 
classification and tariff categories of 2006. (See Appendix 3)  
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 Date of imaging was the date the USS was done.  
 Indication for sonar was considered related to GS if the requesting 
physician documented epigastric or right upper quadrant pain (with or 
without jaundice), a positive Murphy’s sign, or if the requesting 
physician suspected GS. (See Appendix 4) An indication related to GS 
in a patient who subsequently had GS on that particular USS was 
interpreted as symptomatic GS. A patient who had GS on USS but 
whose indication did not meet the criteria considered for symptomatic 
GS above was classified as having asymptomatic GS. As over 60 
different categories of USS indications were collected, they were 
grouped along similar clinical features and reduced to 14 groups to 
allow for data analysis. Indications that specifically pointed to GS and 
other biliary system pathology were grouped under biliary pathology. 
 Gallstones were considered present if the sonographer documented 
with certainty the visualisation of GS on sonar. Where the sonographer 
was not certain or doubted whether GS were present or not, this was 
interpreted as absent GS.  
 The site of GS was defined as the site of the visualised GS 
documented by the sonographer. 
 Complications of GS were defined as documented sonographic 
evidence of known GS complications in a patient with sonograhic 
evidence of GS. They could either be cholecystitis, choledocholithiasis, 
cholangitis, pancreatitis or other complications which were further 
specified. 
2.5.3 Data Quality Control 
Data for the study was collected by the researcher who is a specialist physician and 
gastroenterologist. The researcher was assisted by the medical officers and interns 
who were attached to the gastroenterology unit. This was to allow correct 
interpretation of medical terms especially when capturing the indication for USS and 
when reading the ultrasound findings. 
Missing data from the USS reports were completed by using the medicom system. 
This was necessary as all the USS reports did not document patient race and in 
cases where patient demographic data was manually entered by the requesting 
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physician there would be some missing data and this was commonly seen with SEC 
and date of birth. In patients who had multiple USS done, only data from the initial 
USS was captured. Where any handwritten patient data was conflicting, the 
medicom electronic system was considered the most accurate. Duplicates were 
identified and removed where appropriate.  
2.5.4 Data Processing Methods and Analysis 
Data was collected and coded using a Microsoft Office Excel 2007 spreadsheet. 
Categorical variables were described using frequencies. Normally distributed 
continuous variables were described using means and standard deviations and non-
normally distributed continuous variables were described using medians and inter-
quartile ranges. The overall prevalence of GS, the prevalence of asymptomatic, 
symptomatic and complicated GS were calculated using percentages. Exact 
binomial 95% confidence intervals (CI) were estimated for the overall GS 
prevalence.  
 Pearson chi squared test of proportions was used to compare characteristics of 
patients with GS and those without GS. The two sample T test was used to compare 
mean age of those with GS and those without. Using STATA version 13 (STATA 
Corporation, College Station, TX), unadjusted (univariate) and adjusted (multivariate) 
logistic regression models were fitted to explore risk factors for GS using the 
following factors: gender, race, age, SEC and type of ward.  Results where 
appropriate will be reported as means +/- standard deviation. 
 
2.6 Ethical Considerations 
To protect the identities of participants, unique patient identifiers were used to 
replace patient names and hospital numbers. A separate sheet with patient 
identifying numbers corresponding to patient names was kept in an encrypted 
password protected file in the gastroenterology department. Patient names, hospital 
numbers and dates of birth were maintained after collecting data from the USS 
reports to allow completion of data by searching the medicom system. This was 
necessary to improve accuracy e.g. in situations where patients had similar names 
or missing hospital numbers etc. Patients with similar names were differentiated 
using hospital numbers and date of birth. These patient identifiers were however 
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removed from the data once data collection and cleaning was complete. The data 
was then analysed without any patient identifiers. 
 Data were stored in the student’s personal laptop which has password restricted 
access.  The information obtained from this study will be used to improve care at 
CMJAH and at other health care facilities in the country. Ethical approval was sought 
and was granted by the University of Witwatersrand Human Research Ethics 
Committee (medical). The ethics clearance certificate M140230 approved 25th May 
2014 is attached. (See Appendix 5) Permission to carry out the study was sought 
and granted by the hospital authorities. Letter of approval is attached (See Appendix 
6).  
The study had originally been designed to include all USS reports done over a two 
year period however expert statisticians recommended that the study had reviewed 
an adequate number of USS over one year. This advice was based on the calculated 
minimum sample size of 292. (See Appendix 1) The relevant documents regarding 
this change of the study period to one year are attached. (See Appendix 7 and 8) 
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Chapter 3: Results 
 
Introduction 
In this chapter, the results of the study are presented with the aim of fulfilling the 
objectives of the study. This chapter initially describes the overall characteristics of 
the study sample before showing the prevalence rate of GS among the different 
study population categories. The prevalence of GS complications as well as a 
description of the type of complications found in the study is reported. The chapter 
concludes with a description of the patient characteristics that are associated with 
GS.  
3.1 Study Sample Description 
The overall description of the patients who were included in the study is shown in 
Table 3.1. A total of 3 494 USS reports were analysed and included in the study. 
Forty-four percent (1 524) were male and 1 965 (56.2%) were female and gender 
was unknown in 5 patients (0.1%). Most of the patients were Black 2 514 (72%) and 
race was unknown in 29 (0.8%) patients. The mean age  was 47 +/- 17.5 years. Half 
of the patients 1 748 (50%) were in a low socio-economic class (H1).Nearly two 
thirds of patients (63.2%) were inpatients and the rest were outpatients. Indications 
for ultrasound imaging varied with the commonest being malignancy related 
pathology 571(16.3%). Only 4.4% of patients were scanned for specific biliary 
pathology. In 73 (2.1%) of the cases the indication for the ultrasound scan was 
unknown. 
3.2 The Prevalence of Gallstones 
The overall prevalence of GS was 8.1% (95% CI 7.2 - 9.1). (See Table 3.2) The 
prevalence of GS among females was significantly higher at 10.2% compared to the 
males at 5.5% with a male: female ratio of 1:2. Gallstone prevalence was 
significantly lowest in Black patients who had a prevalence of 6.1% compared to 
White, Asian and Coloured patients who had  prevalence of 13.7%, 11.9%, 12.5% 
respectively. The mean age of patients with GS was a decade older at 56.4 +/- 17.5 
years compared to those who did not have GS. Regarding socioeconomic 
classification, GS prevalence was highest among pensioners (H0)  
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Table 3.1 : Overall Patient Characteristics (N=3 494) 
 
 
 
 
  
Characteristics (n) (%) 
Gender 
Male 
Female 
Unknown 
 
1 524(43.62) 
1 965(56.24) 
5(0.14) 
Race 
Black 
White 
Asian 
Coloured 
Unknown 
 
2 514(71.95) 
703(20.12) 
160(4.58) 
88(2.52) 
29(0.83) 
Age (years) 
Mean (SD) 
 
46.95(17.46) 
Socioeconomic class(SEC) 
H0(pensioners) 
H1(low SEC) 
H2(Medium SEC) 
H3(High SEC) 
Medical aid patients 
Emergency patients 
Private ward (Folateng) 
Unknown 
 
 
529(15.14) 
1 748(50.03) 
622(17.80) 
5(0.14) 
441(12.62) 
36(1.03) 
111(3.18) 
2(0.06) 
 
Ward 
Inpatients 
Outpatients 
 
2 208(63.19) 
1 286(36.81) 
 
Indication for ultrasound scan 
Malignancy work up 
Trauma & Post surgical complications 
Nephro-urogenital 
Liver pathology  
Abdominal pain/discomfort/tenderness 
Tuberculosis 
Gynaecological 
Sepsis/Ascites 
Biliary pathology 
Other 
Abdominalmass/distension/swelling/hernia 
Unknown 
Pancreatic pathology 
Splenic pathology 
 
 
 
571(16.34) 
507(14.51) 
477(13.65) 
424(12.14) 
338(9.67) 
249(7.13)  
203(5.81) 
186(5.32) 
153(4.38) 
149(4.26) 
126(3.61)        
73(2.09) 
20(0.57) 
18(0.52) 
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Table 3.2: Patient Characteristics by gallstone status (N=3 494) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Two-sample T test 
Characteristics No 
Gallstones 
n (%) 
Gallstones 
n (%) 
p value for 
Pearson ᵡ2 
test 
Gender 
Male 
Female 
 
1 441(94.55) 
1 765(89.82) 
 
 
83 (5.45) 
200 (10.18) 
 
< 0.001 
Race 
Black 
White 
Asian 
Coloured 
 
 
 
2 361(93.91) 
607(86.34) 
141(88.13) 
77(87.50) 
 
153(6.09) 
96 (13.66) 
19(11.88) 
11(12.50) 
 
<0.001 
Age 
Mean (Standard deviation) 
46.12 (17.22) 56.39 
(17.45) 
<0.001* 
Socioeconomic class(SEC) 
H0& Emergency patients 
H1(low SEC) 
H2(Medium SEC) 
H3 & Private ward 
Medical aid patients 
 
498 (88.14) 
1 640(93.82) 
581 (93.41) 
102(87.93) 
387 (87.76) 
 
 
67 (11.86) 
108 (6.18) 
41(6.59) 
14(12.07) 
54 (12.24) 
 
 
<0.001 
Ward 
Inpatients 
Outpatients 
 
 
2 048(92.75) 
1 162(90.36) 
 
160 (7.25) 
124 (9.64) 
 
0.012 
Indication for ultrasound scan 
Nephro-urogenital 
Gynaecological 
Abdominal mass/distension/swelling/hernia 
Abdominal pain/discomfort/tenderness 
Trauma & Post surgical complications 
Sepsis/Ascites 
Liver pathology 
Pancreatic pathology 
Biliary pathology 
Malignancy workup 
Splenic pathology 
TB 
Other 
 
 
 
435 (91.19) 
193 (95.07) 
113 (89.68) 
295 (87.28) 
504 (99.41) 
179 (96.24) 
385 (90.80) 
17 (85.00) 
112 (73.20) 
516 (90.37) 
17 (94.44) 
240 (96.39) 
142 (95.30) 
 
 
42 (8.81) 
10(4.93) 
13 (10.32) 
43 (12.72) 
3 (0.59) 
7 (3.36) 
39 (9.20) 
3 (15.00) 
41 (26.80) 
55 (9.63) 
1 (5.56) 
9 (3.61) 
7(4.70) 
 
<0.001 
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and those of high SEC i.e. medical aid patients and H3 & private ward patients, 
compared to those in lower SECs. GS prevalence among inpatients was significantly 
lower at 7.3% compared to that among outpatients which was 9.6%.The highest 
prevalence of GS when classified by indication for USS was seen among patients 
being investigated for biliary pathology (26.8%) and the lowest prevalence was seen 
amongst patients being imaged for trauma or post surgical complications (0.6%).  
3.3 The Ratio of Symptomatic to Asymptomatic Gallstones 
The respective proportions of symptomatic and asymptomatic GS are shown in 
Figure 3.1. Among all the patients with GS, 93 (32.8%) were symptomatic and 180 
(63.4%) were asymptomatic. The ratio of symptomatic to asymptomatic GS was 
1:1.9 (See Figure 3.1). Information regarding gallstone symtomatology was 
unavailable in 11(3.9%) of patients.  
 
Figure 3.1: Symptomatic and asymptomatic gallstones  
3.4 Correlation of clinical symptoms with ultrasound findings 
Only a third of patients presenting with GS symptoms were confirmed to have GS on 
ultrasound. Symptoms in keeping with symptomatic GS were also observed in 
11.65% of patients who did not have GS on ultrasound imaging. (See Table 4.3)The 
sensitivity of GS symptoms in correctly identifying those with GS on ultrasound was 
34% while the specificity was 88%.The positive predictive value of GS symptoms 
was 19.9% and the negative predictive value was 93%. 
No Gallstones 
92% 
Asymptomatic 
63% 
Symptomatic 
33% 
Missing 
4% Gallstones 
8% 
Symptomatic and asymptomatic 
gallstones  
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Table 3.3:  Correlation of clinical symptoms with ultrasound findings 
 No gallstone 
symptoms 
N (%) 
Gallstone 
symptoms 
N (%) 
Missing 
N (%) 
Total 
N (%) 
No 
Gallstones 
2 771(93.90) 374(80.09) 65(85.53) 3 210(91.87) 
Gallstones 180(6.10) 93(19.91) 11(14.47) 284(8.13) 
Total 2 951(100) 467(100), 76(100) 3 494(100) 
Pearson Chi 2  p <0.001 
Gallstone symptoms were frequently documented in patients being imaged for liver 
pathology (36.9%), abdominal pain, discomfort or tenderness (23.5%) and biliary 
pathology (26.2%). (See Table 3.4) 
 
Table 3.4: Frequency of gallstone symptoms per ultrasound indication 
Indication for ultrasound Frequency of GS 
symptoms 
Percentage 
Malignancy work up 3 0.80 
Trauma & Post surgical complications 3 0.80 
Nephro-urogenital 5 1.34 
Liver pathology  138 36.90 
Abdominal pain/discomfort/tenderness 88 23.53 
Gynaecological 2 0.53 
Sepsis/Ascites 28 7.49 
Biliary pathology 98 26.20 
Other 2 0.53 
Abdominal 
mass/distension/swelling/hernia 
2 0.53 
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Pancreatic pathology 5 1.34 
Total 374 100 
 
3.4 Complications of gallstones 
 The majority of GS patients [266 (93.7%)] had no complications. Complications 
were seen in 6.3% of all GS cases. Complications were seen in 19.35% of patients 
who had symptomatic GS. 
There were various complications of GS seen in the study which are shown in Figure 
3.2. The most commonly observed complication was cholecystitis 11 (61.1%). Other 
complications noted were choledocholithiasis 3 (16.7%), pancreatitis 2 (11.1%) and 
cholangitis 2 (11.1%). 
 
 
Figure 3.2: Types of gallstone complications observed in the study 
3.5 Factors associated with gallstones 
We explored the following factors for association with GS: gender, race, age, SEC 
and type of ward. Table 3.5 shows the unadjusted and adjusted logistic regression 
analysis. In unadjusted logistic regression, factors associated with GS were female 
gender [OR 1.97(1.51-2.56)], White race [OR 2.44(1.86-3.20)], Asian/Coloured race 
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[OR 2.12(1.40-3.22)], increasing age [OR 1.03(1.03-1.04)], H0 & emergency patients 
[OR 2.04(1.48-2.82)], H3 & private ward [OR 2.08(1.15-3.77), medical aid patients 
[OR 2.12 (1.50-2.99) and inpatients [OR0.73( 0.57-0.94)]. 
In adjusted analysis, ward and SEC were no longer significantly associated with GS.  
Female gender [OR 1.87(1.42-2.46)], White race [OR 1.40(1.01- 1.93)] and 
increasing age [OR 1.03(1.02-1.04)] were significantly associated with GS.                                                                                                                                                               
Table 3.5: Factors associated with gallstones  
Factor Unadjusted logistic regression 
OR (95% CI) P Value 
Adjusted logistic 
regression 
OR (95% CI) P Value 
Gender 
Male 
Female 
 
1 
1.97 (1.51–2.56) <0.001 
 
1 
1.87 (1.42-2.46) <0.001 
Race 
Black 
White 
Asian/Coloured 
 
1 
2.44 (1.86-3.20) <0.001 
2.12 (1.40-3.22) <0.001 
 
 
1 
1.40 (1.01-1.93)  0.041 
1.52 (0.99-2.34)  0.058 
Age 1.03 (1.03-1.04 )<0.001 1.03 (1.02-1.04) <0.001 
Socioeconomic 
class(SEC) 
H1(low SEC) 
H0& Emergency 
patients 
H2(Medium SEC) 
H3 & Private ward 
Medical aid patients 
 
1 
2.04 (1.48-2.82) <0.001 
1.07 (0.74-1.55)   0.715 
2.08 (1.15-3.77)   0.015 
2.12 (1.50-2.99) <0.001 
 
1 
1.04 (0.73-1.50)  0.822 
1.21 (0.82-1.77)  0.333 
1.38 (0.74-2.60)  0.313 
1.23 (0.82-1.85)  0.324 
Ward 
Outpatients 
Inpatients 
 
1 
0.73 (0.57-0.94)   0.013 
 
1 
0.81 k(0.62-1.06)  0.120 
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Chapter 4: Discussion 
 
Introduction 
This study was a retrospective cross sectional analysis of USS reports which aimed 
to describe the demographic, clinical and sonographic features of GS occurring in 
adult patients undergoing abdominal ultrasonography in the radiology department at 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH). The study specifically 
looked at GS prevalence, symptoms and complications of GS as well as risk factors 
for developing GS in our study population. 
The findings of the study are discussed below according to the suggested structure 
for discussion of scientific papers by Docherty and Smith (153). The discussion will 
be structured as: statement of principal findings, findings in relation to other studies 
and finally strengths and limitations of the study in relation to other studies. 
4.1 Principal Findings 
 We conducted a retrospective cross sectional analysis of 3 494 abdominal 
ultrasound scan reports from 2009 and found that 284 (8.1%) had GS. The 
prevalence of GS was 10.2% and 5.5% among females and males respectively, with 
a female: male ratio of 2:1. The prevalence of GS among Whites, Coloureds, Asians 
and Blacks was 13.7%, 12.5%, 11.9% and 6.1% respectively. The ratio of 
symptomatic to asymptomatic GS was 1:1.9. The sensitivity and specificity of GS 
symptoms in correctly identifying those with GS on ultrasound was 34% and 88% 
respectively. The positive predictive value of GS symptoms was 19.9% and the 
negative predictive value was 93%. 
The prevalence of GS complications among those with GS was 6.3% with the 
commonest observed complication being cholecystitis 11 (61.1%). Independent risk 
factors for GS were female gender [OR 1.97(1.51-2.56)], increasing age [OR 
1.03(1.02-1.04)] and white race [OR 2.44(1.86-3.20)]. 
4.2 Findings in relation to other studies. 
4.2.1 Study sample characteristics 
The majority of patients in our study were black. This is a reflection of the general 
demographics of South Africa as 79.2% of the South African population is 
black(105). Our mean age was very similar to the Ghanaian study which had a mean 
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age of 47 (+/-18) years. Our study had more females than males which was similar 
to other studies (123,124,131,136,138,139).  
Half of our patients were in a low SEC i.e. H1. This is a reflection of the South 
African demographics as shown in a report by Statistics South Africa and the 
National Treasury. This report stated that 55% of South Africans were below the 
2006 indigence line of R2 400 per household per month(154).This is comparably 
similar to the H1 SEC classification used in this study. (See appendix 3) This finding 
may however not be similar to the private hospital patient profile as our study was 
conducted in a public institution. Our study had a higher proportion of pensioners 
compared to the national average of 6.5% which would be found in the general 
population (105). Pensioners are more likely to seek medical care due to age, and 
probably for financial reasons they are more likely to attend a public health care 
facility. 
 
More than half of our study subjects were inpatients. This study was carried out at a 
tertiary referral institution where patients admitted there are likely to be complicated 
and needing multiple investigations including abdominal USS. No distinction in 
hospital admission status of patients was made in other hospital based studies (137–
139,145,155,156). 
The most frequent indication for abdominal USS in our study was in patients being 
investigated for malignancy. This is probably because USS is the most readily 
available radiological imaging to look for occult malignancy at CMJAH. This was 
different from data from Ethiopia and India which saw the highest number of 
investigations being requested for renal disease and pregnancy respectively 
(139,157). 
4.2.2 Overall prevalence of gallstones 
The overall prevalence of GS in our study of 8.1% was much lower than the general 
prevalence of GS in the western populations particularly in studies done in North 
America and Europe which showed prevalence rates of 10% -15% and 5.9% -21.9% 
respectively (12,119). Our prevalence however was higher than that of < 5% 
described for sub-Saharan Africa by other authors (11,12). This difference might 
arise from the fact that this earlier data was based on population studies done on 
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very small numbers in populations that were not comparable with the South African 
population such as the Masaai tribe (134,135).The Masaai are a nomadic tribe who 
live a predominantly active, rural life and are not exposed to urbanisation, obesity, 
high dietary fat and a sedentary lifestyle unlike the modern South African population    
(108–112,116,134). Therefore the non existence of GS among the Masaai cannot be 
generalised to all African populations. 
The overall prevalence in our study is  higher when compared to other recent 
population based African studies namely Sudan and Tunisia which have GS 
prevalence of 5.2% and 4% respectively (135,136). It is possible that the higher 
prevalence seen could be as a result of our study being hospital based compared to 
community based studies. Our study had higher prevalence compared to other 
hospital based surveys in Africa, namely Ethiopia and Ghana which showed GS 
prevalence of 5.2% and 5.9% respectively% (138,139). Our study however had a 
lower prevalence compared to that of 17.5% noted among Nigerian diabetic patients 
(145). The Nigerian study was conducted amongst a select high risk population of 
diabetic patients hence the higher prevalence observed. Our prevalence was lower 
than that observed in two hospital based Indian studies which had prevalence of 
11.1% and 29.7% (156,157).  
4.2.3 Gallstone prevalence in relation to gender 
The GS prevalence among females in our study was similar to that seen among 
females in the Soweto study (140). The higher ratio of females with GS in our study 
was expected as females have a higher risk of developing GS compared to males 
(12). Conversely the studies in Ethiopia and Sudan showed a male: female ratio of 
1:1. This may explain why our study has a higher overall GS prevalence than seen in 
Ethiopia and Sudan as we had a higher number of females with GS. Another 
explanation for the equal prevalence of GS among males and females in these 
studies could be the low level of exposure to hormonal contraception of women in 
these countries. Only 4.8% of women in Sudan and 13.2% in Ethiopia are exposed 
to hormonal contraception compared to 39.4% in South Africa. (158) Use of 
hormonal contraception and hormone replacement therapy (HRT) is associated with 
increased risk of developing GS (11,12,73,159). Some Asian studies also showed 
significantly higher GS prevalence in males compared to females while others 
showed no significant difference in male and female prevalence (42,61,126,141). 
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This may result from them having more of pigment than cholesterol GS (11,127). 
Pigment stones may not show the same relationship with gender as do cholesterol 
stones since pigment stones are not influenced by factors such as endogenous sex 
hormones, pregnancy, parity, OCP and HRT. We however were unable to type GS in 
our study in order to accurately compare with other studies whether GS subtype had 
any influence on gender prevalence.  
4.2.4 Gallstone prevalence in relation to race 
Prevalence of GS was highest among Whites and least among Black individuals. 
These results when compared to American data are similar in that American Blacks 
have the lowest GS prevalence as well (12). They are however dissimilar in that 
American Indians tend to have the highest prevalence of GS amongst all American 
races unlike the population in South Africa (12).The different genetic makeup of 
American and South African racial groups does not allow for  accurate comparison 
between them. There is no literature that explores race in gallstone disease on the 
African continent. There is a possibility that the existing data on African GS surveys 
is based on studies carried out in populations that are less racially diverse. Our study 
was hospital based and this may explain the difference between our findings and 
American data. 
 
4.2.5 Gallstone prevalence in relation to patient hospital status 
More outpatients had GS compared to inpatients. This is likely due to the fact that 
most GS remain asymptomatic, negating the need for admission to hospital (90,160). 
Hence the finding of a higher GS prevalence among outpatients compared to 
inpatients. 
4.2.6 Gallstone prevalence in relation to SEC 
Higher GS prevalence was noted in pensioners and in those of higher SEC. 
Pensioners being older individuals have a higher risk of GS compared to younger 
individuals. They are more likely to be female as well as there are more females than 
males over the age of 65 in South Africa (105).Female gender increases GS risk. 
This further increases the GS risk among pensioners.  Those in the higher SECs are 
likely to be more urbanised and consume a more westernised diet hence putting 
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them at risk of developing GS. This finding was also described in other studies 
(129,130). 
 However some work done in the USA showed an inverse relationship between SEC 
and GS prevalence (148). Variations in methods used to define SEC may account 
for this discrepancy in findings. The American study used four measures of SEC i.e. 
occupation, education, income and residential neighbourhood whereas ours only 
used income or assets. The Ethiopian study used rural and urban dwelling as SEC, 
but a comparison of these two groups was not made available in their results (139). 
The study in Xinjiang, China used the regional economy of the study site as SEC 
and compared it to findings from regions in China with different economies and 
showed that GS were commoner in lower SEC regions (127). An Indian study of 
1 695 adults used a modified Kuppuswamy's classification for SEC, which is based 
on occupation, education, and monthly income. Their results failed to show a 
difference in GS prevalence among all SECs in this study (161). We were also 
unable to find a statistically significant association between SEC and GS. 
 In our study there were fewer patients in the higher SECs hence any patients with 
GS in these classes were likely to reflect a higher prevalence. For example out of 
only 5 H3 patients in the study, one had GS resulting in a GS prevalence of 20% 
among H3 patients. This being a public institution based study we may not have 
accurately represented higher SEC patients as they are more likely to afford private 
health care and thus not be included in our study. 
4.2.7 Gallstone prevalence in relation to indication for ultrasound 
The highest prevalence of GS was seen in patients undergoing USS for biliary 
pathology. This was expected as gallstones form in the biliary system and symptoms 
they give rise to, are consistent with biliary disease and were more likely to be 
documented as such by the requesting physician. This is different from a hospital 
based study in India where most GS were seen among pregnant women (157). This 
could have resulted from pregnant women constituting the largest proportion of their 
sample (28.3%) and also from the fact that pregnancy is a risk factor for GS. 
4.2.8 Ratio of Symptomatic to Asymptomatic Gallstones 
As expected the prevalence of GS related symptoms among those who had GS was 
higher than that of 10-20% described in the population based natural history of GS 
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(160). The ratio of symptomatic to asymptomatic GS of 1:1.9 in our study was 
different from that of 1:1 seen in another hospital based study in Ethiopia (139). 
However  data from both our study and the Ethiopian study showed higher 
proportions of symptomatic GS than in population based studies (129,130,162).This 
discrepancy in results may arise from bias introduced by  hospital based studies 
which are more likely to include more symptomatic patients than would  community 
based studies. A community based study in Argentina however showed that just over 
half of the patients with GS in Buenos Aires were symptomatic (123).This result is 
unusual for a community based study as most GS are expected to be asymptomatic 
(11,160).  
The sensitivity of GS symptoms in correctly identifying those who had gallstones was 
very low as a sizeable proportion of patients without GS had matching symptoms. 
This was probably because symptoms arising from other abdominal organs such as 
the liver can mimic symptomatic GS. This is further supported by the fact that 
patients being imaged for liver disease and those who presented with non specific 
abdominal pain, discomfort or tenderness constituted 37% and 24% respectively of 
all patients who were classified as symptomatic GS.  
A study in Peru that was comparing high and low altitude dwelling populations 
concluded that abdominal pain was a poor indicator of GS as it was equally 
prevalent between those who had GS and those who did not have GS (122). Safer et 
al showed that typical biliary pain had a specificity of 97.6% which was much higher 
than ours of 88%(136). Theirs being a prospective study was probably able to 
uniformly interview patients with minimal subjectivity. 
In a Danish study of 3 608 adults, the positive predictive values of abdominal 
symptoms ranged from 0% to 25.0% while the negative predictive value ranged from 
93.2% to 94.2% (143). These findings were similar to our findings of 34% positive 
predictive value and 93% negative predictive value. These findings reinforce the 
unreliability of clinical symptoms alone in correctly identifying patients with 
symptomatic GS. 
4.2.9 Complications of Gallstones 
Prevalence of gallstone complications in our study was higher than 0.2% which was 
seen among pregnant women in Nigeria. Our findings however were much lower 
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than that of 22.1% seen in the Ethiopian hospital based survey (139). Cholecystitis 
was our commonest complication as in other studies, however in Ethiopia their 
commonest complication was choledocholithiasis (137,139).Perhaps this could result 
from GS in Ethiopian patients primarily forming in the bile ducts as opposed to the 
gallbladder suggestive of pigment stones, however this subject was not addressed in 
their study.  
As our study was done retrospectively, we may have missed complications that are 
better diagnosed clinically e.g. cholangitis and this may account for the lower 
complication prevalence observed in our study when compared to other hospital 
based studies (3,139,163). The prevalence of complications observed among 
patients with symptomatic GS in our study was 19.4% compared to 5.8% found at a 
referral hospital in India (156). Almost all complicating GS are preceded by one or 
more episodes of biliary symptoms (164). 
4.2.10 Factors Associated with Gallstones 
The statistically significant association between female gender and GS is well 
established in literature (11,12,136,138,159). Studies conducted in Iran showed very 
low GS prevalence of 0.8%-1.8% (132,133). Women were under-represented in 
these study samples due to cultural practices yet there was a statistically significant 
association between female gender and GS. The strong association between female 
gender and GS may be related to female reproductive hormones, use of the 
hormonal contraception, HRT or parity, however this study was not specifically 
designed to investigate these risk factors (12,27,165). 
 Some studies however have shown different results. In a Japanese survey of 2 584 
volunteers from the Okinawa community, the overall GS prevalence was 3.2% with 
4.0% for females and 2.5% for males. The risk factors for GS in this study were 
increasing age and fatty liver on ultrasound. There was no statistically significant 
association between GS and female gender (125). In a Chinese study comparing the 
Han and the Uinghur ethinic groups, female gender was a significant GS risk factor 
in the Uinghur ethnic group only (127). The Uinghur group were more westernised in 
their diet and developed cholesterol GS as opposed to the Han group who 
developed mostly pigment stones (127). Female gender may be a risk factor for 
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developing cholesterol GS and not pigment stones which have a different 
pathophysiology. However more research is needed to confirm this. 
Our study also showed a statistically significant association between White race and 
GS, this is similar to findings in the United States that show that White Americans 
had a higher GS prevalence than Black Americans (12). There may be underlying 
race specific genetic variations in genes responsible for bile and cholesterol 
metabolism pathways that result in varying GS prevalence among different racial 
groups.  
 The association between increasing age and GS noted in our study is also similar to 
other previous studies (11,136,138,145). It has been proposed that aging increases 
length of exposure to GS risk factors (166). 
4.3 Strengths of the study in relation to other studies 
We included both males and females. This is in contrast to other studies that 
primarily focused on specific populations such as elderly women, pregnant women 
and diabetics (137,140,145). This eliminated bias that may arise from studying only 
one specific group of individuals e.g. females only as it is known that female gender 
is associated with a higher risk of developing GS (11,12).  
This study involved all the population groups (races) that are formally recognised in 
South Africa i.e. Blacks, Whites, Asians and Coloureds (105). This is comparable 
with the North and South American surveys   which documented the differences in 
GS prevalence among different races and ethnic groups (118,167).There are no 
other studies on the African continent that investigated racial differences in GS 
prevalence and our study seems to be the only study conducted in Africa that 
explored this issue.  
Our study included all ages above 18 years. This is in contrast to the Soweto study 
which specifically recruited elderly women with an age range of 55-85 years old and 
the Taiwanese study which concentrated on only the elderly in a rural community 
(140,166). As increasing age is a risk factor for GS, studies with a higher mean age 
may result is a higher prevalence of GS (11). The French study excluded individuals 
under 30 years of age due to poor study compliance as a result their results do not 
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accurately represent the entire French adult population specifically the younger 
adults (142). 
 
Our study explored SEC of patients using personal or household income and assets. 
Socio-economic classification was not explored in most of the studies done in Africa. 
The study done in Ethiopia classified patients into rural and urban dwellers based on 
their addresses and used this as SEC (139). This may not be an accurate way of 
assessing SEC as the study did not consider personal or family income/assets as 
was done in our study.  
4.4 Limitations of the study in relation to other studies 
Our study as with most other retrospective record reviews was prone to effects of 
confounding, missing and incorrect data. The electronic ‘medicom’ data capturing 
system was vital in capturing data that was not initially available on the USS reports. 
However the medicom system classified patients who were referred to the CMJAH 
radiology department for USS from smaller health care centres as outpatients. This 
is despite the fact that some of these patients were actually admitted at these 
referring health care centres and may not be comparable to mobile and clinically 
stable outpatients coming for USS from CMJAH outpatient clinics with whom they 
were put in the same category.  
The USS reports were hand written and in certain instances the indication for the 
investigation was illegible or the request form was missing this resulted in the 
inability of the investigators to accurately classify GS as either symptomatic or 
asymptomatic. As a result information pertaining to symptomatology of GS was 
missing in 4% of our GS patients. 
 Classification of GS into either symptomatic or asymptomatic was based on the 
information provided by the USS requesting doctor. Not all doctors provided all the 
relevant patient information on the requesting forms and this may have misled USS 
report interpretation. The ultrasound request form is not filled in any systematic way. 
As a result there were over 60 USS indications that had to be grouped into similar 
groups to allow for data analysis. Grouping of indications may have introduced bias.  
The collection of symptoms used in the study to define GS symptoms is not specific 
to GS disease alone and can arise from other abdominal organs. As a result the 
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sensitivity and positive predictive value of symptom based diagnosis of GS were very 
low in this study. The CMJAH socio-economic classification is based on patient self 
reported income and salary slips where ever possible. It is vulnerable to inaccuracy 
as patients may misrepresent themselves in order to qualify for a lower fee paying or 
non paying SEC category. This may explain why there was no significant relationship 
between SEC and GS. 
It was not possible to exclude previously symptomatic GS patients who may now 
have had a scan for an indication that was unrelated to their GS. This may have 
resulted in them being misclassified as asymptomatic. This is in contrast to other 
studies that were done prospectively and were spared from these challenges 
(136,137,145).  
 It is worth noting that obstetric ultrasounds at CMJAH are done in a separate 
dedicated obstetric unit and that data was therefore not captured in this study, this 
resulted in the exclusion of a known high risk group from the study. Our study, unlike 
work done prospectively in Nigeria and Tunisia was not able to assess other possible 
GS risk factors such as BMI, cholesterol levels or exposure to hormonal 
contraception (136,137,145).  
The diagnosis of GS complications in this study was limited to those described by 
the sonographer. This study may therefore have missed some complications of GS 
that are more accurately diagnosed clinically such as cholangitis, as outlined in the 
Tokyo guidelines (3,163). There were instances were sonographers could not state 
with certainty whether GS were present or absent, these cases were classified as 
absent GS. This may have missed some GS which may have needed an alternative 
imaging modality to be more readily visualised. 
Our study was conducted at a tertiary referral hospital where complicated and 
gravely ill patients are often referred for specialist assessment and intervention. This 
may have resulted in our study sample including more patients with symptomatic and 
complicated GS than would be found in the community or at primary and secondary 
health care centres.  
This being a hospital based study may have overestimated the true community 
based GS prevalence in South Africa. This is in contrast to community based studies 
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such as that done by Safer et al (136).The findings of our study are therefore not 
generalisable to the general population but are useful in predicting prevalence of GS 
in public hospital populations in South Africa. 
Our study was unable to explore the types of GS among our patients as was done in 
another study (127). The prevalent risk factors in the South African population would 
favour the development of cholesterol GS but we were unable to investigate this. 
The data from this study is from a public hospital and it is likely that findings from a 
private institution may show different results to ours. 
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Chapter 5: Conclusions and Recommendations 
 
Introduction 
This chapter discusses the meaning and implication of the study. It also addresses 
recommendations for clinicians and policy makers as well as highlights areas of 
possible future research in relation to this subject. 
5.1 Conclusions 
The overall prevalence of GS in this study was higher than that of less than 5% 
previously for Sub-Saharan Africa in literature (11,12). The prevalence of 
complications among all who had GS was 6.3% which was lower than that described 
in an Ethiopian hospital based study (139). Complications among those who had 
symptomatic GS was higher than our overall complication prevalence at 19.4%. The 
sensitivity and positive predictive value of GS symptoms in correctly identifying those 
with GS were low. This shows that clinical symptoms alone are an unreliable 
identifier of patients with symptomatic GS. Risk factors for GS were female gender, 
increasing age and white race. Race is an important but unexplored risk factor for 
GS in African populations. It is possible that the increasing urbanisation, obesity, 
metabolic syndrome and sedentary lifestyle may be resulting in a higher prevalence 
of GS among South Africans than was previously described for Sub-Saharan Africa. 
5.2 Recommendations 
In view of our findings, health care workers should be trained to promptly recognise 
clinical symptoms of symptomatic or complicated GS and have a high index of 
suspicion in older females of white race. Clinical symptoms alone cannot be relied 
upon to accurately identify patients with GS as similar symptoms commonly occur in 
patients without GS. Ultrasound services should be readily available as USS can 
readily confirm the presence or absence of this common digestive disorder. 
Our specialist training programme will need to ensure that all our graduating health 
care workers particularly general surgeons are confident in management of GS 
disease as this is a common disease. Policies which encourage implementation of 
public health education of the South African population on a healthier lifestyle 
(healthier diet, weight loss programmes and exercise etc) may result in a decrease in 
GS prevalence ultimately saving the health system some money.  
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 Digitalisation of the radiology department will enable electronic documentation, 
capturing and storage of USS reports in a non ambiguous format that will allow 
correct interpretation of data by all who need access to it for clinical care of patients 
as well as research. It will also prevent loss of data that may occur if data is stored 
as hard copy reports. A systemised structured ultrasound request form would make it 
more accurate to collect data for research.   
In view of the fact that this was a hospital based study, a community based 
prospective study is recommended to more accurately ascertain the true prevalence 
of GS in the South African general population. A private institution based study 
would also be useful to compare our findings. The impact of obesity, sedentary 
lifestyle, dyslipidaemia and the metabolic syndrome on the prevalence and type of 
GS in South Africa should also be investigated. 
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Appendices 
APPENDIX 1: Sample Size Calculation 
In this calculation the following assumptions were made: 
α =   0.05 (two-sided) 
 Power =   0.9 
 Null hypothesis: p=0.052 (The prevalence of ultrasound diagnosed GS in patients 
who have had an ultrasound at a hospital in Ethiopia was found to be 5.2%. 
Alternative hypothesis:  p (postulated prevalence) =   0.1 (We expect the prevalence 
to be higher in urban Johannesburg given the westernised lifestyle and obesity). 
 
 
  
             n =      292
Estimated required sample size:
 alternative p =   0.1000
         power =   0.9000
         alpha =   0.0500  (two-sided)
Assumptions:
Test Ho: p = 0.0520, where p is the proportion in the population
  to hypothesized value
Estimated sample size for one-sample comparison of proportion
. sampsi 0.052 0.1, power(0.9) onesample
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APPENDIX 2: Ultrasound scan request form 
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APPENDIX 3: Socio-economic Classification 
JOHANNESBURG HOSPITAL 
CLASSIFICATION AND TARRIF CATEGORIES BASED ON INCOME AND STATUS 
AS FROM 1/1/2006 
OUT-PATIENTS (CLINICS) 
NB: ALL FINANCIAL CATEGORIES ARE NOW FULLY UPFS RATES 
FINANCIAL CLASSIFICATION CODES FOR COMPUTER 
COMPUTER 
CODE 
INCOME/ASSETS 
FOR INDIVIDUAL 
INCOME/ASSETS 
FOR FAMILY UNIT 
TARRIFS 
CLINICS 
H0 FORMALLY UNEMPLOYED 
SOCIAL PENSIONER 
FREE 
H1 Annual income less than R36 000 
Assets less than R151 200 
 
Annual income less than R50 000 
Assets less than R231 300 
R40 
H2 Annual income R36 000 - R72 0000 
Assets for R151 200 – R321 200 
 
Annual income R50 000 – R100 000 
Assets not more than R231 300 – R473 300 
R120 
H3 Annual income R72 000 and more or 
Assets worth more than R321 200 
 
Annual income R100 000 and more or 
Assets worth more than R473 300 
R172 
PM 1. A member of a medical scheme 
2. Prisoners awaiting trial 
3. Prisoners already sentenced 
R172 
H2 An applicant where income/information is not readily available 
 
R120 
HD SADF Members – Must have DD63- if not be classified according to income. Defence 
Force requires that the original pink copy of the DD 2703 be forwarded to the Accounts 
Department. 
UPFS(Bills 
to be raised 
by Patient 
Accounts) 
PP Foreign patients (Exclusively for medical treatment, visitors or emergencies) Permission 
from clinical executive must be obtained. Deposit/guarantee must be obtained. An 
applicant as identified in regulation 4(2) Refusing to give income – provisional 
classification [Hospital patient on request to be treated by a private practitioner]. 
 
R172 
 
Free codes 
U6 Children under 6 ( Excluding medical aid patients) 
HG All hospital patients that are exempted from paying 
WC Injury on duty – see foot note 
PG Private patients 
CC Committed children 
SW SW – Injury on duty- Staff 
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APPENDIX 4: Data collection sheet 
 
 
DEMOGRAPHIC INFORMATION 
Study Number     : _____________________________ Date of imaging : __________ 
Age                      : ___________ Ward                   : __________ 
Sex                       :     Male                              Female 
Race                     :    Black                   White                            Asian                      Other specify :____ 
Patient Class        :      H0                  H1                                  H2                  H3 Other specify :____ 
*Please see appendix 2 
INDICATION FOR SONAR 
         Related to gallstones                                                      Not related to gallstones   
      Specify:______________________                                Specify: ______________________ 
(*epigastric or right upper quadrant pain(+/- jaundice) or a positive Murphy’s sign, or if the requesting physician 
suspected gallstones                            
SONAR FINDINGS 
                                                  Gall bladder seen             Gall bladder not seen 
                                                                                                                     Cholecystectomy 
                                                                                                                     Other Specify   _________    
Gall stones                   :            Present             Absent      
Gall stones site            :            Gall bladder                                          Biliary tree 
Number of gall stones : Single       Multiple 
COMPLICATIONS OF GALLSTONES ON SONAR 
        Cholecystitis                                       Cholangitis 
        Pancreatitis                                                                 Choledocholithiasis 
        Other  specify : ______________________                                             
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APPENDIX 5: Ethics Clearance Certificate 
  
 68  
 
APPENDIX 6: Letter of study approval 
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APPENDIX 7: Application for change of study title 
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APPENDIX 8: Approval of change of study title 
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APPENDIX 9: Permission to reproduce previously published material 
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APPENDIX 10: Permission to reproduce previously published material 
 
 
 
 
 
 
 
 
